Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide

International Journal of Oncology

Volumn 41, Issue 3, 2012, Pages 876-884

  Kawano, Yawara ^a   Fujiwara, Shiho ^a   Wada, Naoko ^a   Izaki, Mikiko ^a   Yuki, Hiromichi ^a   Okuno, Yutaka ^a   Iyama, Kenichi ^b   Yamasaki, Hiroshi ^c   Sakai, Akira ^d   Mitsuya, Hiroaki ^a   Hata, Hiroyuki ^a,e  

^a KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^b KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

^c KUMAMOTO CITY HOSPITAL   (Japan)

^d FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^e KUMAMOTO UNIVERSITY   (Japan)

Author keywords

CD138; IRF4; Lenalidomide; Multiple myeloma

Indexed keywords

B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; BORTEZOMIB; INTERFERON REGULATORY FACTOR 4; LENALIDOMIDE; PROTEIN BCL 6; SYNDECAN 1; TRANSCRIPTION FACTOR PAX5; X BOX BINDING PROTEIN 1;

ADULT; AGED; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER RELAPSE; CANCER SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MYELOMA CELL; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

AGED; APOPTOSIS; B-CELL-SPECIFIC ACTIVATOR PROTEIN; BORONIC ACIDS; CELL LINE, TUMOR; DNA METHYLATION; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; FEMALE; FLOW CYTOMETRY; HUMANS; INTERFERON REGULATORY FACTORS; MULTIPLE MYELOMA; PHENOTYPE; PROGNOSIS; PYRAZINES; REPRESSOR PROTEINS; SYNDECAN-1; THALIDOMIDE; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84865011312     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1545     Document Type: Article

References (31)

1. Calame KL: Plasma cells: finding new light at the end of B cell development. Nat Immunol 2: 1103-1108, 2001.
2. Dhodapkar MV, Abe E, Theus A, et al: Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth, and bone cell differentiation. Blood 91: 2679-2688, 1998. (Pubitemid 28227516)
3. Ridley RC, Xiao H, Hata H, Woodliff J, Epstein J and Sanderson RD: Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen. Blood 81: 767-774, 1993. (Pubitemid 23040870)
4. Wijdenes J, Vooijs WC, Clement C, et al: A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. Br J Haematol 94: 318-323, 1996. (Pubitemid 26247990)
5. Zhan F, Huang Y, Colla S, et al: The molecular classification of multiple myeloma. Blood 108: 2020-2028, 2006. (Pubitemid 44395016)
6. Ikeda H, Hideshima T, Fulciniti M, et al: The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res 15: 4028-4037, 2009.
7. Witzig TE, Kimlinger T, Stenson M and Therneau T: Syndecan-1 expression on malignant cells from the blood and marrow of patients with plasma cell proliferative disorders and B-cell chronic lymphocytic leukemia. Leuk Lymphoma 31: 167-175, 1998. (Pubitemid 28428760)
8. Reid S, Yang S, Brown R, et al: Characterisation and relevance of CD138-negative plasma cells in plasma cell myeloma. Int J Lab Hematol 32: e190-e196, 2010.
9. Matsui W, Huff CA, Wang Q, et al: Characterization of clonogenic multiple myeloma cells. Blood 103: 2332-2336, 2004. (Pubitemid 38326254)
10. Harada H, Kawano MM, Huang N, et al: Phenotypic difference of normal plasma cells from mature myeloma cells. Blood 81: 2658-2663, 1993. (Pubitemid 23147570)
11. Ohmori M, Nagai M, Fujita M, et al: A novel mature B-cell line (DOBIL-6) producing both parathyroid hormone-related protein and interleukin-6 from a myeloma patient presenting with hypercalcaemia. Br J Haematol 101: 688-693, 1998. (Pubitemid 28308518)
12. Togawa A, Inoue N, Miyamoto K, Hyodo H and Namba M: Establishment and characterization of a human myeloma cell line (KMM-1). Int J Cancer 29: 495-500, 1982. (Pubitemid 12114621)
13. Namba M, Ohtsuki T, Mori M, et al: Establishment of five human myeloma cell lines. In Vitro Cell Dev Biol 25: 723-729, 1989. (Pubitemid 19216412)
14. Ohtsuki T, Yawata Y, Wada H, Sugihara T, Mori M and Namba M: Two human myeloma cell lines, amylase-producing KMS-12-PE and amylase-non-producing KMS-12-BM, were established from a patient, having the same chromosome marker, t(11;14)(q13;q32). Br J Haematol 73: 199-204, 1989. (Pubitemid 19256112)
15. Nilsson K, Bennich H, Johansson SG and Ponten J: Established immunoglobulin producing myeloma (IgE) and lymphoblastoid (IgG) cell lines from an IgE myeloma patient. Clin Exp Immunol 7: 477-489, 1970.
16. Birnie GD: The HL60 cell line: a model system for studying human myeloid cell differentiation. Br J Cancer (Suppl) 9: 41-45, 1988.
17. Mahmoud MS, Huang N, Nobuyoshi M, Lisukov IA, Tanaka H and Kawano MM: Altered expression of Pax-5 gene in human myeloma cells. Blood 87: 4311-4315, 1996. (Pubitemid 26155029)
18. Tatetsu H, Ueno S, Hata H, et al: Down-regulation of PU.1 by methylation of distal regulatory elements and the promoter is required for myeloma cell growth. Cancer Res 67: 5328-5336, 2007. (Pubitemid 46997272)
19. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001. (Pubitemid 34164012)
20. Matsuno N, Hoshino K, Nanri T, et al: p15 mRNA expression detected by real-time quantitative reverse transcriptase-polymerase chain reaction correlates with the methylation density of the gene in adult acute leukemia. Leuk Res 29: 557-564, 2005. (Pubitemid 40327244)
21. Shapiro-Shelef M and Calame K: Regulation of plasma-cell development. Nat Rev Immunol 5: 230-242, 2005. (Pubitemid 40364824)
22. Lopez-Girona A, Heintel D, Zhang LH, et al: Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response. Br J Haematol 154: 325-336, 2011.
23. Li S, Pal R, Monaghan SA, et al: IMiD immunomodulatory compounds block C/EBP{beta} translation through eIF4E down-regulation resulting in inhibition of MM. Blood 117: 5157-5165, 2009.
24. Peceliunas V, Janiulioniene A, Matuzeviciene R and Griskevicius L: Six color flow cytometry detects plasma cells expressing aberrant immunophenotype in bone marrow of healthy donors. Cytometry B Clin Cytom 80: 318-323, 2011.
25. Bataille R, Jego G, Robillard N, et al: The phenotype of normal, reactive and malignant plasma cells. Identification of 'many and multiple myelomas' and of new targets for myeloma therapy. Haematologica 91: 1234-1240, 2006. (Pubitemid 44408434)
26. Pope B, Brown RD, Gibson J, Yuen E and Joshua D: B7-2-positive myeloma: incidence, clinical characteristics, prognostic significance, and implications for tumor immunotherapy. Blood 96: 1274-1279, 2000. (Pubitemid 30658455)
27. Lin P, Mahdavy M, Zhan F, Zhang HZ, Katz RL and Shaughnessy JD: Expression of PAX5 in CD20-positive multiple myeloma assessed by immunohistochemistry and oligonucleotide microarray. Mod Pathol 17: 1217-1222, 2004. (Pubitemid 39312948)
28. Hideshima T, Mitsiades C, Ikeda H, et al: A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells. Blood 115: 3772-3775, 2010.
29. Fuhler GM, Baanstra M, Chesik D, et al: Bone marrow stromal cell interaction reduces syndecan-1 expression and induces kinomic changes in myeloma cells. Exp Cell Res 316: 1816-1828, 2010.
30. Matsui W, Wang Q, Barber JP, et al: Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res 68: 190-197, 2008. (Pubitemid 351380120)
31. Brennan SK, Wang Q, Tressler R, et al: Telomerase inhibition targets clonogenic multiple myeloma cells through telomere length-dependent and independent mechanisms. PLoS One 5: e12487, 2010.